Speaker: Date: Topic
J. Thomas Lamont, MD
June 11, 2014
Clostridium Difficile 2014: More Difficult Than Ever
Responsibility for Content
The WebEx video, PowerPoint presentation, take-away points, and article links were sent by the Medical Library and the CME Committee.
Diane E. Young, Information Specialist
Take-Away Points of the Presentation
1. Incidence, severity and relapse are rising.
2. Host immune response is critical.
3. Vanco > Flagyl for severe disease.
4. Make sure that it is Clostridium Difficile.
5. Role of Fidaxomicin is still unclear ($$$).
6. Stool transfer when all else fails.
7. Vaccine development is promising.
Links to Articles Cited in the Presentation
- Aslam S: Treatment of Clostridium difficile-associated disease: old therapies and new strategies. La
- Bavishi C: Systematic review: the use of proton pump inhibitors and increased susceptibility to ente
- Cohen SH: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by
- Cornely OA: Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus van
- Howell MD: Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infe
- Kelly CP: Fecal microbiota transplantation--an old therapy comes of age. NEJM 2013;368(5):474-5.
- Kyne L: Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxi
- Louie TJ: Fidaxomicin versus vancomycin for Clostridium difficile infection. NEJM 2011;364(5):422-31
- McCarthy DM: Proton pump inhibitor use and Clostridium difficile colitis: cause or coincidence? J Cl
- McDonald LC: An epidemic, toxin gene-variant strain of Clostridium difficile. NEJM 2005;353(23):2433
- Persky SE: Treatment of recurrent Clostridium difficile-associated diarrhea by administration of don
- Sethi AK: Persistance of skin contamination and environmental shedding of Clostridium difficile duri
- Viscidi R: Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983;148